Projecting future drug expenditures--2009
- PMID: 19179637
- DOI: 10.2146/ajhp080636
Projecting future drug expenditures--2009
Abstract
Purpose: Drug expenditure trends in 2007 and 2008, projected drug expenditures for 2009, and factors likely to influence drug expenditures are discussed.
Summary: Various factors are likely to influence drug expenditures in 2009, including drugs in development, the diffusion of new drugs, drug safety concerns, generic drugs, Medicare Part D, and changes in the drug supply chain. The increasing availability of important generic drugs and drug safety concerns continue to moderate growth in drug expenditures. The drug supply chain remains dynamic and may influence drug expenditures, particularly in specialized therapeutic areas. Initial data suggest that the Medicare Part D benefit has influenced drug expenditures, but the ultimate impact of the benefit on drug expenditures remains unclear. From 2006 to 2007, total U.S. drug expenditures increased by 4.0%, with total spending rising from $276 billion to $287 billion. Drug expenditures in clinics continue to grow more rapidly than in other settings, with a 9.9% increase from 2006 to 2007. Hospital drug expenditures increased at a moderate rate of only 1.6% from 2006 to 2007; through the first nine months of 2008, hospital drug expenditures increased by only 2.8% compared with the same period in 2007.
Conclusion: In 2009, we project a 0-2% increase in drug expenditures in outpatient settings, a 1-3% increase in expenditures for clinic-administered drugs, and a 1-3% increase in hospital drug expenditures.
Similar articles
-
Projecting future drug expenditures--2010.Am J Health Syst Pharm. 2010 Jun 1;67(11):919-28. doi: 10.2146/ajhp100068. Am J Health Syst Pharm. 2010. PMID: 20484216
-
Projecting future drug expenditures--2008.Am J Health Syst Pharm. 2008 Feb 1;65(3):234-53. doi: 10.2146/ajhp070629. Am J Health Syst Pharm. 2008. PMID: 18216009
-
Projecting future drug expenditures--2012.Am J Health Syst Pharm. 2012 Mar 1;69(5):405-21. doi: 10.2146/ajhp110697. Am J Health Syst Pharm. 2012. PMID: 22345420
-
National trends in prescription drug expenditures and projections for 2016.Am J Health Syst Pharm. 2016 Jul 15;73(14):1058-75. doi: 10.2146/ajhp160205. Epub 2016 May 11. Am J Health Syst Pharm. 2016. PMID: 27170624 Review.
-
Projecting future drug expenditures--2005.Am J Health Syst Pharm. 2005 Jan 15;62(2):149-67. doi: 10.1093/ajhp/62.2.149. Am J Health Syst Pharm. 2005. PMID: 15700889 Review.
Cited by
-
Using pharmacoeconomic modelling to determine value-based pricing for new pharmaceuticals in malaysia.Malays J Med Sci. 2011 Oct;18(4):32-43. Malays J Med Sci. 2011. PMID: 22589671 Free PMC article.
-
An Anticancer Drug Unit for the whole provincial oncologic network of Piacenza: improving safety and savings.Med Oncol. 2015 Feb;32(2):457. doi: 10.1007/s12032-014-0457-y. Epub 2015 Jan 9. Med Oncol. 2015. PMID: 25572812
-
Utilization of Pharmaceutical Patient and Prescription Assistance Programs via a Pharmacy Department Patient Assistance Program for Indigent Cancer Patients.Hosp Pharm. 2016 Jul;51(7):572-6. doi: 10.1310/hpj5107-572. Hosp Pharm. 2016. PMID: 27559190 Free PMC article.
-
Drug waste minimization as an effective strategy of cost-containment in oncology.BMC Health Serv Res. 2014 Feb 7;14:57. doi: 10.1186/1472-6963-14-57. BMC Health Serv Res. 2014. PMID: 24507545 Free PMC article.
-
Stability of infliximab in polyvinyl chloride bags.Am J Health Syst Pharm. 2012 Sep 1;69(17):1509-12. doi: 10.2146/ajhp100116. Am J Health Syst Pharm. 2012. PMID: 22899746 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical